Page last updated: 17th February 2022

The NMDT brings together representatives from all the infusion Centres and others so that there is joint and equitable national decision making about the operation and delivery of the Zolgensma programme.

On the NMDT there are three individuals from each of the four infusion centres (consultant, physiotherapist and one other) plus a specialist pharmacist, an SMA expert and a consultant from one of the Regional Neuromuscular Centres.

The NMDT meets weekly and initially worked on the many operational aspects of this new national programme. They now carefully discuss children who have been referred to them. It can take a considerable amount of time to discuss each child.

Communication from the NMDT about children is to consultants in referring Specialist Neuromuscular Centres who will contact families.

If a child has received Zolgensma but there is disease progression, the NHS England Clinical Panel gives advice to clinicians at treatment centres. This panel also advises clinicians about nusinersen and risdiplam treatment.